Perspective Therapeutics, Inc. (CATX)

Market Cap	540.44M +305.4%
Revenue (ttm)	884,000 -39.2%
Net Income	-103.12M
EPS	-1.40
Shares Out	114.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,338,548
Open	4.630
Previous Close	4.640
Day's Range	4.520 - 4.800
52-Week Range	1.930 - 6.160
Beta	1.87
Analysts	Strong Buy
Price Target	12.11 (+155.49%)
Earnings Date	May 11, 2026

About CATX

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-α-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 166
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CATX

Financial Performance

In 2025, Perspective Therapeutics's revenue was $884,000, a decrease of -39.20% compared to the previous year's $1.45 million. Losses were -$103.12 million, 30.1% more than in 2024.

Analyst Summary

According to 9 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price target is $12.11, which is an increase of 155.49% from the latest price.

Price Target

$12.11

(155.49% upside)

Analyst Consensus: Strong Buy